24/01/2018
DGAP-News: SHOP APOTHEKE EUROPE N.V. / Key word(s): Development of Sales/Preliminary Results NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.
Dr. Ulrich Wandel, CFO of SHOP APOTHEKE EUROPE, comments on the financial year 2017: "Overall, we are very satisfied with our successful growth in the financial year 2017. We have increased the share of our international revenues significantly from 17% in 2016 to c. 26% in 2017 and have consistently continued to invest in the expansion and automation of our warehouse, logistics and IT infrastructure. With the acquisition of Europa Apotheek, we have broadened our product range with prescription drugs for additional German and future international growth. With an overall +60% increase in revenues, we have achieved our ambitious target for 2017 and once again substantially expanded our market leadership in all relevant European markets. In this way, we have created the base for continued strong growth in our European target markets in the financial year 2018." SHOP APOTHEKE EUROPE will publish the detailed results for the financial year 2017 with presentation of the consolidated financial statements on 12 March 2018.
SHOP APOTHEKE EUROPE is the leading and fastest growing online pharmacy in continental Europe. With the acquisition of Europa Apotheek Venlo in November 2017, SHOP APOTHEKE EUROPE significantly enhanced its European market leadership with an extended product range for the whole family in the areas of OTC, beauty and care products as well as prescription drugs. SHOP APOTHEKE EUROPE already operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and The Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to about 2.7 m active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services. SHOP APOTHEKE EUROPE N.V. has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016. Trade and public media: Financial media: Investor Relations:
This publication is an advertisement. Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Group's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and the Group does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.
24.01.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | SHOP APOTHEKE EUROPE N.V. |
Dirk Hartogweg 14 | |
5928 LV Venlo | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | ulrich.wandel@shop-apotheke.com |
Internet: | www.shop-apotheke-europe.com |
ISIN: | NL0012044747 |
WKN: | A2AR94 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |